Arvinas Inc - Aset Bersih saben Siji Saham ARVN

Logo perusahaan publik Arvinas Inc (ARVN)

Arvinas, Inc. (ARVN) possesses immense market leverage, as the need for tumor therapy is critical. The company is implementing a method for the complete degradation of pathogenic proteins within cells. The business relies on the development of drugs to combat prostate and breast cancer. This daily price chart captured the 8.69 metric. The asset's prospects are tied to test results and a partnership with a major pharmaceutical behemoth.

Arvinas Inc (ARVN) - Nilai Akuntansi saben Saham saka 04.07.2022 nganti 28.10.2026

Ringkesan rincian data analitis arvinas.com (ARVN)

- rega lan prakiraan konsensus rega:
Kutipan saham Arvinas Corp|ARVN - Bagan rega target
- data kapitalisasi pasar:
Nilai pasar Arvinas, Inc.|ARVN - Nilai Bisnis
- data kapitalisasi buku:
Nilai Buku saben Saham Arvinas|ARVN - Aset Bersih Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku arvinas.com|ARVN - Total Aset Perusahaan
- data utang lan likuiditas:
Utang marang Ekuitas Arvinas, Inc.|ARVN - Rasio utang jangka dawa marang modal|Utang jangka cendhak marang modal Arvinas|ARVN - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Arvinas, Inc.|ARVN - Utang jangka dawa|Utang jangka cendhak perusahaan Arvinas
Analisis kabeh metrik perusahaan:Arvinas Corp, ARVN
Produk asil prodhuksi arvinas.com

Investors seek an equilibrium between asset quality and market price. The book value per share reflects the portion of equity attributable to a single security, excluding price volatility. For Arvinas, Inc. (ARVN), this metric confirms the capitalization of intellectual property and PROTAC patents. High R&D expenditures form the business's material base. By analyzing changes in BVPS, one can assess the stability of the company's net asset accumulation.